micalcet 60 mg tabletki powlekane
zentiva, k.s. - cinacalcetum - tabletki powlekane - 60 mg
micalcet 90 mg tabletki powlekane
zentiva, k.s. - cinacalcetum - tabletki powlekane - 90 mg
cinacalcet medice 30 mg tabletki powlekane
medice arzneimittel puetter gmbh & co. kg - cinacalcetum - tabletki powlekane - 30 mg
cinacalcet medice 60 mg tabletki powlekane
medice arzneimittel puetter gmbh & co. kg - cinacalcetum - tabletki powlekane - 60 mg
cinacalcet medice 90 mg tabletki powlekane
medice arzneimittel puetter gmbh & co. kg - cinacalcetum - tabletki powlekane - 90 mg
imatinib vipharm 100 mg kapsułki twarde
vipharm s.a. - imatinibum - kapsułki twarde - 100 mg
imatinib vipharm 400 mg kapsułki twarde
vipharm s.a. - imatinibum - kapsułki twarde - 400 mg
bikalutamid farmax 50 mg tabletki powlekane
svus pharma a.s. - bicalutamidum - tabletki powlekane - 50 mg
cinacalcet teva 60 mg tabletki powlekane
teva pharmaceuticals polska sp. z o.o. - cinacalcetii hydrochloridum - tabletki powlekane - 60 mg
verzenios
eli lilly nederland b.v. - abemaciclib - nowotwory piersi - Środki przeciwnowotworowe - early breast cancerverzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative, node positive early breast cancer at high risk of recurrence (see section 5. in pre or perimenopausal women, aromatase inhibitor endocrine therapy should be combined with a luteinising hormone-releasing hormone (lhrh) agonist. advanced or metastatic breast cancerverzenios is indicated for the treatment of women with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. in pre- or perimenopausal women, the endocrine therapy should be combined with a lhrh agonist.